The Generics Bulletin Podcast: Recent And Upcoming Industry Events

Our Editorial Team Discusses Conferences From Recent Months Through Into Early 2025

Generics Bulletin’s editorial team discusses recent conferences held by Medicines for Europe and the AAM, while looking ahead to the key off-patent industry events that are on the calendar over the next few months and beyond.

Generic Bulletin Podcast

This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss recent off-patent industry events such as the legal and annual conferences held by Medicines for Europe in Dublin in June and the annual meeting of the US Association for Accessible Medicines earlier this year, while also looking ahead to the key off-patent industry events on the calendar over the next few months and beyond.

Citeline · The Generics Bulletin Podcast: Recent And Upcoming Industry Events

Open Media

Generics Bulletin reported on Medicines for Europe’s June conferences in a series of articles published earlier this year. (Also see "Medicines For Europe Highlights Sector Challenges As It Celebrates Milestone Anniversary" - Generics Bulletin, 17 June, 2024.)

This included a detailed report on the concluding panel of industry leaders. (Also see "The View From The Top: European CEOs Highlight Industry Priorities" - Generics Bulletin, 27 June, 2024.)

We also previously brought you coverage from the AAM’s annual conference, including an interview with chair Keren Haruvi. (Also see "‘Is The Market Now Sustainable? The Answer Is Still Not’: AAM’s Haruvi On The Need To Fix The US Generics Industry" - Generics Bulletin, 13 February, 2024.)

The AAM event also closed with a leaders’ panel. (Also see "The Long Read: CEOs Unplug At AAM Conference" - Generics Bulletin, 15 February, 2024.)

More from Generics

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By 

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By 

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

More from Conferences

IGBA’s Susana Almeida On Consensus Building, Harmonization, And Policy Built On Science – Not Politics

 

IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.

After A Decade Of US Biosimilars, ‘The Challenges Are Becoming More Clear’

 
• By 

As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.

In Discussion With Medicines For Europe: Bracing For US Tariffs And Embracing Ukraine

 

Tariffs, international cooperation, and war: the off-patent industry is not immune to the political issues raging across the globe. Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska spoke with Generics Bulletin about what these developments mean for the sector.